Rehabilitation of Everyday Memory Impairment in Parkinson Disease: A Pilot Study



Status:Recruiting
Conditions:Parkinsons Disease
Therapuetic Areas:Neurology
Healthy:No
Age Range:50 - Any
Updated:5/3/2014
Start Date:June 2011
Contact:Tasha Doty, MA
Email:dotyt@npg.wustl.edu
Phone:314-362-7160

Use our guide to learn which trials are right for you!

Cognitive impairment is common among non-demented individuals with Parkinson disease (PD)
and is a significant source of disability and reduced quality of life. Unfortunately, there
are no successful interventions to address these impairments. Prospective memory impairment
is a particularly functionally- and clinically-relevant problem in PD. The investigator's
project will determine if a targeted intervention strategy improves PD participants'
prospective memory. The investigator's goal is to improve PD patients' everyday prospective
memory so they can successfully perform desired activities and roles.

Cognitive impairment is common among non-demented individuals with Parkinson disease (PD)
and is a significant source of disability and reduced quality of life. Unfortunately, there
are no successful interventions to address these impairments. Prospective memory impairment
is a particularly functionally- and clinically-relevant problem in PD. The investigator's
project will determine if a targeted intervention strategy improves PD participants'
prospective memory. The investigator will use a randomized controlled design and a
laboratory-based assessment of prospective memory to test the effect of the strategy in a
controlled environment. The investigator will also see if PD participants, with support from
an occupational therapist (OT), can generalize the strategy to their complex, real-world
environments and tasks. Our goal is to improve PD patients' everyday prospective memory so
they can successfully perform desired activities and roles.

Inclusion Criteria:

- Participants will be males and females over age 50 who meet criteria for idiopathic
typical PD, are Hoehn & Yahr39 stage I-III (mild-moderate disease) and are treated
with levodopa/carbidopa.

Exclusion Criteria:

- Possible dementia,

- treatment with certain medications that interfere with cognition (e.g.,
anticholinergics),

- change in medications over the study period, other neurological disorders, brain
surgery (e.g., STN DBS),

- history of psychotic disorder or significant current psychiatric disorder, or any
condition that would interfere with testing (e.g., vision problems).
We found this trial at
1
site
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials